4591
RIBOMIC Inc.
リボミック
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
91,963
Mar 2022
80,909
Mar 2023
65,969
Mar 2024
-
Mar 2025
2,107
Operating profit(thousand JPY)
Mar 2021
-1,239,643
Mar 2022
-1,748,112
Mar 2023
-1,786,041
Mar 2024
-1,116,193
Mar 2025
-1,050,589
Operating profit margin(%)
Mar 2021
-1,347.98
Mar 2022
-2,160.59
Mar 2023
-2,707.39
Mar 2024
-
Mar 2025
-49,861.84
Profit before tax(thousand JPY)
Mar 2021
-1,185,984
Mar 2022
-1,683,544
Mar 2023
-1,651,792
Mar 2024
-1,023,027
Mar 2025
-1,017,729
Profit(thousand JPY)
Mar 2021
-1,187,194
Mar 2022
-1,684,754
Mar 2023
-1,653,002
Mar 2024
-1,024,237
Mar 2025
-1,018,939
Total assets(thousand JPY)
Mar 2021
6,119,660
Mar 2022
4,954,476
Mar 2023
4,583,655
Mar 2024
3,547,257
Mar 2025
3,185,842
Cash and cash equivalents(thousand JPY)
Mar 2021
3,338,038
Mar 2022
2,901,796
Mar 2023
2,825,182
Mar 2024
2,099,743
Mar 2025
1,837,123
Cash flows from operating activities(thousand JPY)
Mar 2021
-1,149,038
Mar 2022
-1,499,224
Mar 2023
-1,708,626
Mar 2024
-932,757
Mar 2025
-996,966
Cash flows from investing activities(thousand JPY)
Mar 2021
-1,699,952
Mar 2022
689,556
Mar 2023
276,353
Mar 2024
177,272
Mar 2025
67,178
Cash flows from financing activities(thousand JPY)
Mar 2021
4,988,530
Mar 2022
354,721
Mar 2023
1,333,771
Mar 2024
27,649
Mar 2025
667,263
Return on equity(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Equity ratio(%)
Mar 2021
98.1
Mar 2022
94.7
Mar 2023
95.7
Mar 2024
95.5
Mar 2025
95.5
Earnings per share(JPY per share)
Mar 2021
-46.17
Mar 2022
-59.95
Mar 2023
-53.14
Mar 2024
-28.7
Mar 2025
-25.21
Net assets per share(JPY per share)
Mar 2021
215.04
Mar 2022
164.33
Mar 2023
122.85
Mar 2024
94.09
Mar 2025
68.26
Dividend per share(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Payout ratio(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.